We are expediting reviews for alternative medicine and/or regimen prior authorization requests
If a drug is on the shortage list and an alternative drug or regimen is supported by the National Comprehensive Cancer Network (NCCN®) guidelines,1 your request will be approved
If a drug is on the shortage list and an alternative drug or regimen is not supported by the NCCN guidelines, then the prior authorization request will be pended for an oncologist review. If appropriate, these requests will be approved for 6 months during the drug shortage.
You do not need to request a new prior authorization for the same medication if you are changing the time between doses, as recommended by the American Society of Clinical Oncology (ASCO). However, when the prior authorization period ends, you need to request a new one to continue therapy.
Paclitaxel, cabazitaxel, Abraxane®
Updated on June 02, 2023
We will continue to monitor these drug shortages and provide additional updates as needed.